Tourette Syndrome Pipeline Review, H2 2018 - Therapeutic Assessment of 8 Companies & Drug Profile Activity - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Tourette Syndrome - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Tourette Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 5, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Tourette Syndrome - Overview Tourette Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Tourette Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tourette Syndrome - Companies Involved in Therapeutics Development Abide Therapeutics Inc Catalyst Pharmaceuticals Inc Neurocrine Biosciences Inc Psyadon Pharmaceuticals Inc SOM Biotech SL Teva Pharmaceutical Industries Ltd Therapix Biosciences Ltd Zynerba Pharmaceuticals Inc For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fplfrf/tourette_syndrome?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006232/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 06:00 PM/DISC: 09/25/2018 06:00 PM


Update hourly